107 related articles for article (PubMed ID: 10190659)
1. Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio.
Kinirons MT; Krivoruk Y; Wilkinson GR; Wood AJ
Br J Clin Pharmacol; 1999 Feb; 47(2):223-5. PubMed ID: 10190659
[No Abstract] [Full Text] [Related]
2. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
Chiou WL; Jeong HY; Wu TC; Ma C
Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
[No Abstract] [Full Text] [Related]
3. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men.
Kinirons MT; O'Shea D; Downing TE; Fitzwilliam AT; Joellenbeck L; Groopman JD; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1993 Dec; 54(6):621-9. PubMed ID: 8275617
[TBL] [Abstract][Full Text] [Related]
4. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
5. Erythromycin breath test.
Watkins PB
Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
[No Abstract] [Full Text] [Related]
6. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity.
McCrea J; Prueksaritanont T; Gertz BJ; Carides A; Gillen L; Antonello S; Brucker MJ; Miller-Stein C; Osborne B; Waldman S
J Clin Pharmacol; 1999 Dec; 39(12):1212-20. PubMed ID: 10586386
[TBL] [Abstract][Full Text] [Related]
7. Predicting drug interactions in vivo from experiments in vitro. Human studies with paclitaxel and ketoconazole.
Jamis-Dow CA; Pearl ML; Watkins PB; Blake DS; Klecker RW; Collins JM
Am J Clin Oncol; 1997 Dec; 20(6):592-9. PubMed ID: 9391548
[TBL] [Abstract][Full Text] [Related]
8. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells.
Takano M; Hasegawa R; Fukuda T; Yumoto R; Nagai J; Murakami T
Eur J Pharmacol; 1998 Oct; 358(3):289-94. PubMed ID: 9822896
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P-450 and other determinants of pharmacokinetics, toxicity, and efficacy in humans.
Collins JM
Clin Cancer Res; 2000 Apr; 6(4):1203-4. PubMed ID: 10778942
[No Abstract] [Full Text] [Related]
10. Race but not age affects erythromycin breath test results in older hypertensive men.
Schwartz JB
J Clin Pharmacol; 2001 Mar; 41(3):324-9. PubMed ID: 11269573
[TBL] [Abstract][Full Text] [Related]
11. Mdr1 limits CYP3A metabolism in vivo.
Lan LB; Dalton JT; Schuetz EG
Mol Pharmacol; 2000 Oct; 58(4):863-9. PubMed ID: 10999959
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
13. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients.
Cakaloglu Y; Tredger JM; Devlin J; Williams R
Hepatology; 1994 Aug; 20(2):309-16. PubMed ID: 7519161
[TBL] [Abstract][Full Text] [Related]
14. Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.
Watkins PB; Turgeon DK; Saenger P; Lown KS; Kolars JC; Hamilton T; Fishman K; Guzelian PS; Voorhees JJ
Clin Pharmacol Ther; 1992 Sep; 52(3):265-73. PubMed ID: 1526083
[TBL] [Abstract][Full Text] [Related]
15. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
17. Hepatic cytochrome P-4503A (CYP3A) activity in the elderly.
Hunt CM; Westerkam WR; Stave GM; Wilson JA
Mech Ageing Dev; 1992 Jun; 64(1-2):189-99. PubMed ID: 1630156
[TBL] [Abstract][Full Text] [Related]
18. The xenobiotic inhibitor profile of cytochrome P4502C8.
Ong CE; Coulter S; Birkett DJ; Bhasker CR; Miners JO
Br J Clin Pharmacol; 2000 Dec; 50(6):573-80. PubMed ID: 11136296
[TBL] [Abstract][Full Text] [Related]
19. Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.
Ward KW; Stelman GJ; Morgan JA; Zeigler KS; Azzarano LM; Kehler JR; McSurdy-Freed JE; Proksch JW; Smith BR
Drug Metab Dispos; 2004 Feb; 32(2):172-7. PubMed ID: 14744938
[TBL] [Abstract][Full Text] [Related]
20. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans.
Sandström R; Knutson TW; Knutson L; Jansson B; Lennernäs H
Br J Clin Pharmacol; 1999 Aug; 48(2):180-9. PubMed ID: 10417494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]